You are here

Mydecine Innovations Group Inc.

Listing Exchange: 
CSE
Status: 
Active
Industry: 
Diversified Industries
Symbol: 
MYCO
CSE Index: 
Currency: 

Mydecine Innovations Group Inc. is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.

You are here

Mydecine Innovations Group Inc. (MYCO)

SEDAR Information

Company Info

Address
1890 – 1075 West Georgia Street
Vancouver, BC V6E 3C9
Canada
Phone
604-687-2038
Email
[email protected]
Website
http://www.mydecineinc.com
Listing date
Friday, October 6, 2023
Transfer Agent
Endeavor Trust Corporation
Auditor
BF Borgers CPA PC

Capitalization

Issued & Outstanding: 
55186001
Reserved for Issuance: 
22583791

Company Officers

David Joshua Bartch, President and Chief Executive Officer
John Ross, Chief Financial Officer and Corporate Secretary
Damon Michaels , Chief Operations Officer
Robert Roscow, Chief Science Officer
Rakesh Jetly, Chief Medical Officer
Jim Gunning, Chief Marketing Officer

Bulletins

05/10/2023

2023-1009 - New Listing - Mydecine Innovations Group Inc. (MYCO)

le 5 octobre/October 2023

The common shares of Mydecine Innovations Inc. have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.